- Trial phase
- IND cleared / Phase 1 ready
- Time to market
- IM-1340 has just received IND clearance and has not yet begun patient dosing. If Phase 1 proceeds successfully, a registrational path would likely require several more years of clinical development.
- Why 2/10
- No hard dated catalyst is scheduled for IM-1340 in the next ~12 months; the IND was cleared in October 2026 enabling a Phase 1 start, but no Phase 1 data readout or regulatory decision date has been announced. The drug is a minor early-stage asset at a company whose valuation is dominated by varegacestat (PDUFA April 28, 2027).
IM-1340 has no near-term binary catalyst; the stock is driven by varegacestat's PDUFA on April 28, 2027. Watch for Phase 1 trial initiation and any early data disclosures, but these are unlikely to move the stock significantly given the early stage. The next company-wide event is Q3 2026 earnings on November 16, 2026.
Price Chart
Executive Summary
IM-1340 is an early-stage, potential first-in-class antibody-drug conjugate (ADC) for advanced solid tumors developed by Immunome Inc. (Nasdaq: IMNM). The FDA cleared its Investigational New Drug (IND) application in late September/early October 2026, enabling the company to begin a Phase 1 clinical trial focused on safety. The specific target antigen has not been publicly disclosed. IM-1340 is a minor pipeline asset at Immunome, which is primarily valued for its lead drug varegacestat (PDUFA April 28, 2027 for desmoid tumors). The stock trades at $19.07 with a strong analyst consensus (mean price target $35.20, 84.6% implied upside), but the company is pre-revenue and burning cash. IM-1340 has no near-term binary catalyst and is unlikely to be a meaningful stock-price driver in the next 12 months.
How It Works
IM-1340 is an antibody-drug conjugate (ADC), a type of cancer therapy that works like a guided missile. It combines an antibody (which seeks out and binds to a specific protein on cancer cells) with a potent chemotherapy drug. The antibody delivers the drug directly to tumor cells, aiming to kill them while sparing healthy tissue. The specific target protein has not been publicly disclosed.
Trial Status
The FDA cleared Immunome's Investigational New Drug (IND) application for IM-1340 in late September/early October 2026, allowing the company to initiate a Phase 1 first-in-human trial focused on safety and tolerability in advanced solid tumors. Patient enrollment has not yet been publicly announced as of mid-November 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 trial initiation announcement (no specific date announced)
- Any early safety/tolerability data disclosures (timing uncertain, likely 2027+)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Immunome Inc. 8-K IMNM ·Originating report